Pregled bibliografske jedinice broj: 1139296
Influence of Ile655Val polymorphism on trastuzumab‐induced cardiotoxicity in early‐stage HER2 positive breast cancer
Influence of Ile655Val polymorphism on trastuzumab‐induced cardiotoxicity in early‐stage HER2 positive breast cancer // Scientific reports, 11 (2021), 14395, 11 doi:10.1038/s41598-021-93634-6 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1139296 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Influence of Ile655Val polymorphism on
trastuzumab‐induced
cardiotoxicity in early‐stage HER2 positive breast
cancer
Autori
Vazdar, Ljubica ; Gabrić, Ivo Darko ; Kruljac, Ivan ; Pintarić, Hrvoje ; Šeparović, Robert ; Kirigin Biloš, Lora Stanka ; Pavlović, Mirjana ; Tečić Vuger, Ana ; Štefanović, Mario
Izvornik
Scientific reports (2045-2322) 11
(2021);
14395, 11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
breast cancer ; HER2 positive ; trastuzumab ; cardiac dysfunction
Sažetak
Trastuzumab has improved the prognosis of HER2 positive breast cancer, but cardiotoxicity remains a concern. We aimed to identify risk factors for trastuzumab-induced cardiotoxicity, with an emphasis on the HER2 Ile655Val single nucleotide polymorphism. This single- center case–control study included 1056 patients with early-stage HER2 positive breast cancer that received adjuvant trastuzumab. Cardiotoxicity was defined as a decline in left ventricular ejection fraction (LVEF) > 15% in patients without previous cardiomyopathy, or > 10% in patients with baseline LVEF of < 50%. Patient characteristics and cardiac parameters were compared in 78 (7.38%) cases and 99 randomly assigned controls, and the polymorphism was genotyped using real-time polymerase chain reaction. Cardiotoxicity was independently associated with advanced age (P = 0.024), lower body mass index (P = 0.023), left breast involvement (P = 0.001), N3 status (P = 0.004), diabetes (P = 0.016), and a family history of coronary artery disease (P = 0.019). Genotype distribution was as follows: A/A (Ile/Ile) was found in 111 (62.7%) patients, A/G (Ile/Val) in 60 (33.9%) patients, and G/G (Val/Val) in 6 (3.4%) patients. The genotype was not associated with cardiotoxicity or the severity of heart failure, reversibility, and recovery time. We found no association between the HER2 Ile655Val polymorphism and trastuzumab-induced cardiotoxicity ; therefore, we do not recommend routine cardiotoxicity-risk stratification using this polymorphism.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Profili:
Hrvoje Pintarić
(autor)
Ljubica Vazdar
(autor)
Mario Štefanović
(autor)
Mirjana Pavlović
(autor)
Ivana Kruljac
(autor)
Ana Tečić Vuger
(autor)
Robert Šeparović
(autor)
Ivo Darko Gabrić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE